News
ADYX
0.0001
NaN%
--
Weekly Report: what happened at ADYX last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at ADYX last week (0401-0405)?
Weekly Report · 04/08 10:33
Weekly Report: what happened at ADYX last week (0325-0329)?
Weekly Report · 04/01 10:32
Weekly Report: what happened at ADYX last week (0318-0322)?
Weekly Report · 03/25 10:35
Weekly Report: what happened at ADYX last week (0311-0315)?
Weekly Report · 03/18 10:33
Weekly Report: what happened at ADYX last week (0304-0308)?
Weekly Report · 03/11 10:31
Weekly Report: what happened at ADYX last week (0226-0301)?
Weekly Report · 03/04 10:33
Weekly Report: what happened at ADYX last week (0219-0223)?
Weekly Report · 02/26 10:42
Weekly Report: what happened at ADYX last week (0212-0216)?
Weekly Report · 02/19 10:43
Weekly Report: what happened at ADYX last week (0205-0209)?
Weekly Report · 02/12 10:36
Weekly Report: what happened at ADYX last week (0129-0202)?
Weekly Report · 02/05 10:42
Weekly Report: what happened at ADYX last week (0122-0126)?
Weekly Report · 01/29 10:34
Weekly Report: what happened at ADYX last week (0115-0119)?
Weekly Report · 01/22 10:37
Weekly Report: what happened at ADYX last week (0108-0112)?
Weekly Report · 01/15 10:34
Weekly Report: what happened at ADYX last week (0101-0105)?
Weekly Report · 01/08 10:37
Weekly Report: what happened at ADYX last week (1225-1229)?
Weekly Report · 01/01 10:33
Weekly Report: what happened at ADYX last week (1218-1222)?
Weekly Report · 12/25/2023 10:42
Weekly Report: what happened at ADYX last week (1211-1215)?
Weekly Report · 12/18/2023 10:45
Weekly Report: what happened at ADYX last week (1204-1208)?
Weekly Report · 12/11/2023 10:42
Weekly Report: what happened at ADYX last week (1127-1201)?
Weekly Report · 12/04/2023 10:42
More
Webull provides a variety of real-time ADYX stock news. You can receive the latest news about Adynxx through multiple platforms. This information may help you make smarter investment decisions.
About ADYX
Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.